AB002

Evidence outlook · lead readout

NCT03963895 · End Stage Renal Disease, Thrombosis

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT03963895: The study was randomized, quadruple-blinded, and placebo-controlled, but it was small, with only 12 participants per group. Its numerous primary safety endpoints were mainly summarized descriptively, and the registry does not report a statistical comparison showing that a prespecified primary endpoint was met; therefore, the findings provide limited evidence despite the strong masking and control design.